The Performance of PLGF Threshold 100pg/mL in Ruling-out Preeclampsia Using Aucheer PLGF Assay
Abstract
out pre-eclampsia in women with suspected pre-eclampsia using the Aucheer PLGF assay. Study Design: 203 samples from women with
suspected preeclampsia were analysed from a prospective cohort study. PLGF levels were measured using the Aucheer PLGF assay, and the
performance of a 100 pg/mL cutoff to rule out pre-eclampsia was assessed. Results: Aucheer PLGF concentration threshold (?100 pg/ml) was
confirmed to have high performance for ruling-out pre-eclampsia within 14 days[Negative predictive value (NPV) 99.3% (95% CI 98.0%,
100%)]and 28 days [NPV 98.0% (95% CI 95.7%, 100%)]. Conclusion: The 100 pg/mL PLGF threshold using the Aucheer PLGF assay demonstrated an excellent performance in ruling out pre-eclampsia, with comparable performance to other established assays, and could be an
alternative for clinical use.
Keywords
Full Text:
PDFReferences
[1] Duley L. The global impact of pre-eclampsia and eclampsia. Semin Perinatol 2009;33: 130137.
[2] Rana S, Lemoine E, Granger JP, Karumanchi SA. Preeclampsia: Pathophysiology, Challenges, and Perspectives.Circ Res. 2019 Mar
29;124(7):1094-1112.
[3] Bokslag A, van Weissenbruch M, Mol BW, de Groot CJ. Preeclampsia; short and long-term consequences for mother and neonate. Early
Hum Dev. 2016 Nov;102:47-50.
[4] Conley MK. Preeclampsia: Short- and Long-Term Effects. Neonatal Netw. 2024 Aug 1;43(4):234-246.
[5] Peixoto-Filho FM, Costa FDS, Kobayashi S, Beitune PE, Garrido AG, Carmo AV, Rezende GC, Junior HW, Junior JA, Leo JRDT,
Nardozza LMM, Machado LE, Sarno MAC, Neto PPF, Jnior EB.Prediction and prevention of preeclampsia. Rev Bras Ginecol Obstet.
2023 Jan;45(1):49-54.
[6] Rolnik DL, Wright D, Poon LC, O'Gorman N, Syngelaki A, de Paco Matallana C, Akolekar R, Cicero S, Janga D, Singh M, Molina FS,
Persico N, Jani JC, Plasencia W, Papaioannou G, Tenenbaum-Gavish K, Meiri H, Gizurarson S, Maclagan K, Nicolaides KH. Aspirin
versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia.N Engl J Med. 2017 Aug 17;377(7):613-622.
[7] Paul TD, Hastie R, Tong S, Keenan E, Hiscock R, Brownfoot FC. Prediction of adverse maternal outcomes in preeclampsia at term.
Pregnancy Hypertens. 2019 Oct;18:75-81.
[8] Wataganara T, Leetheeragul J, Pongprasobchai S, Sutantawibul A, Phatihattakorn C, Angsuwathana S. Prediction and prevention of
preeclampsia in Asian subpopulation. J Obstet Gynaecol Res. 2018 May;44(5):813-830.
[9] Chau K, Hennessy A, Makris A. Placental growth factor and pre-eclampsia. J Hum Hypertens. 2017 Dec;31(12):782-786.
[10] Athanassiades A, Lala PK. Role of placenta growth factor (PIGF) in human extravillous trophoblast proliferation, migration and invasiveness. Placenta 1998; 19(7): 465473.
[11] Chaiworapongsa T, Romero R, Kim YM, Kim GJ, Kim MR, Espinoza J, et al. Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia. J Matern Fetal Neonatal Med 2005; 17: 318
[12] National Institute for Health and Care Excellence. PLGF-based testing to help diagnose suspected pre-eclampsia (Triage PLGF test, Elecysys immunoassay sFlt-1/PLGF ratio, DELFIA Xpress PLGF 12-3 test, and BRAHMS sFlt-1 Kryptor/BRAHMS PLGF plus Kryptor
PE ratio) https://www.nice.org.uk/guidance/dg23, 2016.
[13] Chappell LC, Duckworth S, Seed PT, Griffin M, Myers J, Mackillop L, et al. Diagnostic accuracy of placental growth factor in women
with suspected preeclampsia: a prospective multicenter study. Circulation 2013; 128: 212131.
[14] Duhig KE, Myers J, Seed PT, Sparkes J, Lowe J, Hunter RM, et al. Placental growth factor testing to assess women with suspected preeclampsia: a multicentre, pragmatic, stepped-wedge cluster -randomised controlled trial. Lancet 2019; 393: 180718.
[15] Brown MA, Magee LA, Kenny LC, Karumanchi SA, McCarthy FP, Saito S, et al. International Society for the Study of Hypertension
in Pregnancy (ISSHP).The hypertensive disorders of pregnancy: ISSHP classification, diagnosis & management recommendations for
international practice.Pregnancy Hypertens, 2018;13:291-310
[16] Zeisler H, Hund M, Verlohren S. The sFlt-1:PLGF ratio in women with suspected preeclampsia. N Engl J Med 2016; 374: 17856.
[17] McCarthy FP, Gill C, Seed PT, Bramham K, Chappell LC, Shennan AH. Comparison of three commercially available placental growth
factor-based tests in women with suspected preterm pre-eclampsia: the COMPARE study. Ultrasound Obstet Gynecol 2019; 53: 627.
[18] Cheng YKY, Poon LCY, Shennan A, Leung TY, Sahota DS. Inter-manufacturer comparison of automated immunoassays for the measurement of soluble FMS-like tyrosine kinase-1 and placental growth factor. Pregnancy Hypertens 2019; 17: 16571.
DOI: http://dx.doi.org/10.70711/pmr.v3i3.8644
Refbacks
- There are currently no refbacks.
